Department of Health and Human Services' logo Department of Health and Human Services

Public Health Service
Food and Drug Administration
Southwest Region

 

Denver District Office
Bldg 20, Denver Federal Ctr
6th Ave & Kipling St
Denver, CO 80225-0087
Telephone: 303-236-3000
Fax: 303-236-3551

January 26, 2006
WARNING LETTER
VIA CERTIFIED MAIL, RETURN RECEIPT REQUESTED

John Sichel
Del-Immune VT
6107 Chelsea Manor Ct
Boulder, CO 80301

Ref. No. KAN 2006-06

Dear Mr Sichel:

The Food and Drug Administration (FDA) has reviewed your website at the Internet address www.delimmune.com and has concluded that claims in your labeling cause your product Del-Immune VT™ to be a drug as defined in section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 USC 321(g)(1)(B)]. You can find the Act and FDA's regulations through links on FDA's Internet homepage: www.fda.gov.

Under the Act, articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in man are drugs [Section 201(g)(1)(B) of the Act, 21 USC 321(g)(1)(B)]. Your website claims that your product is useful in the prevention and treatment of influenza.

The Internet labeling of your products bears the following implied claims:

These claims cause your product to be a drug, as defined in section 201(g)(1)(B) of the Act [21 USC 321(g)(1)(B)]. Because your product is not generally recognized as safe and effective when used as labeled, it is also a new drug as defined in section 201(p) of the Act [21 USC 321(p)]. Under section 505 of the Act [21 USC 355 (a)], a new drug may not be legally marketed in the United States without an approved New Drug Application (NDA).

This drug is also misbranded within the meaning of section 502(a) of the Act [21 USC 352(a)] because their labeling is false and misleading in that it suggests that this drug is effective for the prevention and treatment of influenza when, in fact, these claims are not supported by competent and reliable scientific evidence.

Even if your product Del-Immune VT™ did not contain disease claims in its labeling that cause it to be a drug, it would be misbranded as a dietary supplement because your website (www.delimmune.com/default.asp?utm_medium=cpc&utm_campaign=Avian) contains the following statements about this product:

"The product is now produced in the US with the consent to market from the Food and Drug Administration (FDA). The FDA has determined that the product conforms to the guidelines for 'consumer safety' under Natural Supplement Regulations."

These statements are false and misleading. FDA does not approve or grant a "consent to market" for dietary supplements sold in the United States. Further, FDA has not issued any "Natural Supplement Regulations" or guidelines for consumer safety under such regulations. The statements from your website quoted above suggest that FDA has approved or otherwise sanctioned the marketing of your product, and has determined that your product meets FDA safety guidelines. In fact, your product is not approved by FDA, nor has FDA reviewed its formulation or the representations made for it. Moreover, FDA has not determined that your product conforms to any statutory requirement in the Act or to any FDA regulation or guidance issued under the authority of the Act. Therefore, the statements from your website quoted above, which you are using in the promotion of your product, are false and misleading. These false and misleading representations misbrand your product under section 403(a)(1) of the Act.

This letter is not an all-inclusive review of your website and the products that your firm markets. It is your responsibility to ensure that all products marketed by your firm comply with the Act and its implementing regulations.

You must immediately correct these violations. If you do not immediately correct them, you may be subject to enforcement action without notice. The Act provides for seizure of illegal products and for injunctions against the manufacturers and distributors of illegal products [21 USC 332 and 334]. Individuals and businesses that violate the Act may also be subject to criminal prosecution.

Please advise this office, in writing and within fifteen (15) working days of the receipt of this letter, as to the specific steps you haven taken to correct the violations noted above and to ensure that similar violations do not occur. If corrective actions cannot be completed within fifteen working days, state the reason for the delay and the time within which the corrections will be completed.

Your reply should be addressed to Compliance Officer Shelly L. Maifarth at the above address.

Sincerely,
/s/
B. Belinda Collins
District Director

Company's response to FDA

This page was revised on July 13, 2010.

Links to Recommended Companies